| Product Code: ETC7909198 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Latvia Deep Vein Thrombosis Market Overview |
3.1 Latvia Country Macro Economic Indicators |
3.2 Latvia Deep Vein Thrombosis Market Revenues & Volume, 2021 & 2031F |
3.3 Latvia Deep Vein Thrombosis Market - Industry Life Cycle |
3.4 Latvia Deep Vein Thrombosis Market - Porter's Five Forces |
3.5 Latvia Deep Vein Thrombosis Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
4 Latvia Deep Vein Thrombosis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about deep vein thrombosis (DVT) and its risk factors among the population in Latvia |
4.2.2 Growing adoption of advanced diagnostic techniques for early detection of DVT |
4.2.3 Rise in the geriatric population in Latvia, which is more prone to developing DVT |
4.3 Market Restraints |
4.3.1 Limited access to specialized healthcare facilities and expertise in the diagnosis and treatment of DVT in Latvia |
4.3.2 High cost associated with the treatment of DVT, leading to affordability issues for patients |
5 Latvia Deep Vein Thrombosis Market Trends |
6 Latvia Deep Vein Thrombosis Market, By Types |
6.1 Latvia Deep Vein Thrombosis Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Latvia Deep Vein Thrombosis Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Latvia Deep Vein Thrombosis Market Revenues & Volume, By Arixtra (Fondaparinux sodium), 2021- 2031F |
6.1.4 Latvia Deep Vein Thrombosis Market Revenues & Volume, By Fragmin (Dalteparin sodium), 2021- 2031F |
6.1.5 Latvia Deep Vein Thrombosis Market Revenues & Volume, By Eliquis (Apixaban), 2021- 2031F |
6.1.6 Latvia Deep Vein Thrombosis Market Revenues & Volume, By Savaysa (Edoxaban), 2021- 2031F |
6.1.7 Latvia Deep Vein Thrombosis Market Revenues & Volume, By Xarelto (Rivaroxaban), 2021- 2031F |
6.1.8 Latvia Deep Vein Thrombosis Market Revenues & Volume, By Abelacimab, 2021- 2031F |
7 Latvia Deep Vein Thrombosis Market Import-Export Trade Statistics |
7.1 Latvia Deep Vein Thrombosis Market Export to Major Countries |
7.2 Latvia Deep Vein Thrombosis Market Imports from Major Countries |
8 Latvia Deep Vein Thrombosis Market Key Performance Indicators |
8.1 Average time taken for diagnosis of DVT in Latvia |
8.2 Number of healthcare facilities offering specialized DVT treatment in Latvia |
8.3 Percentage of the population in Latvia undergoing regular DVT screenings based on age and risk factors |
9 Latvia Deep Vein Thrombosis Market - Opportunity Assessment |
9.1 Latvia Deep Vein Thrombosis Market Opportunity Assessment, By Drugs, 2021 & 2031F |
10 Latvia Deep Vein Thrombosis Market - Competitive Landscape |
10.1 Latvia Deep Vein Thrombosis Market Revenue Share, By Companies, 2024 |
10.2 Latvia Deep Vein Thrombosis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |